secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0000950170-24-135609
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo: 100% remission in Cohort 1 of mipletamig frontline AML trial; 2 of 3 patients MRD-negative
--------------------------------------------------------------------------------

- 100% of patients (3/3) achieved remission within 30 days in Cohort 1 of RAINIER Phase 1b trial.
- Two patients achieved complete remission with MRD-negative status, including one with TP53 mutation.
- Results build on prior trial where 100% of frontline patients also achieved remission.
- Mipletamig continues to show favorable safety and tolerability profile; Cohort 2 enrollment commencing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024135609/0000950170-24-135609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024135609/apvo-20241212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-135609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer